Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

Value in Health- United Kingdom

doi 10.1016/j.jval.2016.09.2200

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Changing Paradigm of Immunooncology in Advanced Kidney Cancer: Nivolumab and Ipilimumab Combination in the First Line Therapy

Onkourologiya
OncologyRadiologyUrologyNuclear MedicineNephrologyImagingSurgery
2019English

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2017English

Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

Clinical Cancer Research
Cancer ResearchOncology
2016English

Cost-Effectiveness of Nivolumab (NIVO) Combined With Ipilimumab (IPI) Compared With Nivo and Ipi Monotherapies in the First-Line Treatment of Advanced Melanoma in the United States: Analysis Using 28-Month Overall Survival (OS) Data From Checkmate 067

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Healthcare Resource Utilization and Associated Costs in Patients With Advanced Melanoma Receiving First-Line Ipilimumab

Journal of Cancer Therapy
2015English

Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy